Synonyms: BMS-224818 | LEA29Y | Nulojix®
belatacept is an approved drug (FDA (2011), EMA (2011))
Compound class:
Peptide
Comment: A recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). CTLA-4 is essential for T-cell co-activation.
Belatecept differs from abatacept by only 2 amino acids. View more information in the IUPHAR Pharmacology Education Project: belatacept |
Classification | |
Compound class | Peptide |
Ligand families/groups | Immune checkpoint modulators |
Approved drug? | Yes (FDA (2011), EMA (2011)) |
International Nonproprietary Names | |
INN number | INN |
8627 | belatacept |
Synonyms |
BMS-224818 | LEA29Y | Nulojix® |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 247 |
Other databases | |
ChEMBL Ligand | CHEMBL1742990 (Hs) |
DrugBank Ligand | DB06681 |
GtoPdb PubChem SID | 178103474 |
PubChem SID | 135283321 |
Search PubMed clinical trials | belatacept |
Search PubMed titles | belatacept |
Search PubMed titles/abstracts | belatacept |
Wikipedia | Belatacept |